Author:
Xu Na,Liu Xiaoli,Du Qingfeng,Ouyang Lingyun,Liu Zhi,Hou Lijun
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100: 2292–2302
2. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Clin Oncol, 2003, 21: 4642–4649.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood, 2005, 106: 1154–1163.
4. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: cancer and leukemia group B Study 9222. Blood, 2005, 105: 3420–3427.
5. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica, 2004, 89: 998–1008.